ImageneBio Announces $30 Million Private Placement
ImageneBio, Inc. (IMA)
Company Research
Source: GlobeNewswire
Private placement led by Coastlands Capital with participation from additional new and existing investors Proceeds will support further development of IMG-007 in alopecia areata and late-stage development activities for the ongoing program in moderate-to-severe atopic dermatitis IMG-007 is the lead receptor-targeting, non-depleting OX40 antagonist in active clinical development SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA)(“Imagene” or the “Company”) today announced it has entered into a definitive securities purchase agreement with certain institutional investors in a private placement that is expected to result in gross proceeds of approximately $30 million to Imagene, before deducting placement agent fees and other expenses. The company intends to use the proceeds from the offering to support further development of IMG-007 in alopecia areata and late-stage development activities in atopic dermatitis. “We are thrilled to be joined by this exception
Show less
Read more
Impact Snapshot
Event Time:
IMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMA alerts
High impacting ImageneBio, Inc. news events
Weekly update
A roundup of the hottest topics
IMA
News
- Remedy Plan Therapeutics Appoints Jotin Marango, M.D., Ph.D., as Chief Financial and Business Officer [Yahoo! Finance]Yahoo! Finance
- ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- ImageneBio (IMA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "strong sell" toMarketBeat
- ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company UpdateGlobeNewswire
IMA
Sec Filings
- 4/16/26 - Form 3
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- IMA's page on the SEC website